Pharmacogenomics (PGx) Clopidogrel CYP2C19 Test
A targeted pharmacogenomic test evaluating CYP2C19 metabolizer status to optimize clopidogrel prescription and dosing, powered by the Helix Exome+® platform.
Turnaround
6-9 days
Requery (SOQO)
≤ 5 minutes
Genes Tested
1
Panel Description
Clopidogrel is an antiplatelet medication prescribed to patients at increased risk of blood clots, including those who have a history of cardiac events or major cardiac intervention. Clopidogrel prevents the collection of platelets and formation of blood clots in the blood vessels.
Order This Test
Contact our clinical team to order this panel or learn more.
Indications for Testing
Patients in whom clopidogrel therapy is being considered for cardiovascular or neurovascular indications.
Methodology
This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP2C19 and is used to determine drug considerations for Clopidogrel.
Technical Specifications
Reportable range
CYP2C19: *1-*19, *22-*26, *28-*39
Genes Tested
1 genes included in this panel
Ordering Information
Turnaround Time
Typically 6-9 days (standard), Typically ≤ 5 minutes (requery)
Preferred Specimen
BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions
Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Clinical Description
Clopidogrel is an antiplatelet medication prescribed to patients at increased risk of blood clots, including those who have a history of cardiac events or major cardiac intervention. Clopidogrel prevents the collection of platelets and formation of blood clots in the blood vessels.
This test evaluates a patient’s metabolizer status for CYP2C19, which can aid in appropriate prescription and dosing to reduce risk of side effects and treatment failure with clopidogrel.
Ready to order this test?
Contact our clinical team to order the Pharmacogenomics (PGx) Clopidogrel CYP2C19 Test for your patients.